Primary open angle glaucoma: an overview on medical therapy.
The purpose of this review is to discuss the topics relevant to the use of intraocular pressure-lowering strategies, which remains the first line in the management of glaucoma. Estimates of blindness from glaucoma and identification of risk factors remain of interest for all ophthalmologists. New functional tests offer promise for better detection and more accurate diagnosis of glaucoma. We finally discuss the impact of various glaucoma therapies, the principles of monotherapy and fixed combinations, which offer benefits of convenience, cost, and safety.
Vetrugno
Michele
M
Glaucoma Center, Department of Ophthalmology, University of Bari, Bari, Italy. m.vetrugno@oftalmo.uniba.it
Cantatore
Francesco
F
Ruggeri
Giuseppe
G
Ferreri
Paolo
P
Montepara
Alfonso
A
Quinto
Alessandra
A
Sborgia
Carlo
C
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000367:Age Factors; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D004338:Drug Combinations; D005902:Glaucoma, Open-Angle / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure; D008916:Miotics / Q000627:therapeutic use; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D004338:Drug Combinations; D008916:Miotics; D009883:Ophthalmic Solutions; D011453:Prostaglandins